AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research

Article

The AACR and the Prevent Cancer Foundation are pleased to co-sponsor this major international Award in recognition of outstanding cancer prevention research.

The AACR and the Prevent Cancer Foundation are pleased to co-sponsor this major international Award in recognition of outstanding cancer prevention research. The AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research is given to a scientist residing in any country in the world for his or her seminal contributions to the field of cancer prevention. Such investigations must have been conducted in basic, translational, clinical, epidemiological, or behavioral science in cancer prevention research. Further, these studies must have had not only a major impact on the field, but must also have stimulated new directions in this important area.

The recipient of the Award will receive a $5,000 honorarium and present a 50-minute lecture at the 8th Annual AACR International Conference on Frontiers in Cancer Prevention Research. The Conference will be held December 6-9, 2009, at the Hilton Americas, Houston, TX.

The nomination deadline is Friday, July 31, 2009.

For more information: http://www.aacr.org/home/scientists/scientific-achievement-awards/prevent-cancer-award.aspx

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.